Spectral Medical Inc.
TSX:EDT.TOMedical - Diagnostics & Research
-$0.02 today
- Market cap
- $306.00M
- Beta
- 0.23
- P/E (TTM)
- -10.5
- EPS (TTM)
- -$0.13
Volume 0.02M
Average 0.06M
EDT.TO Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Spectral Medical Inc.TSX: EDT.TO
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of CA$233K rose 100.9% year over year, ahead of the +33.8% change in trailing-twelve-month financing cash flow. Sequentially, it fell 84.7% from the prior quarter. Over 3 fiscal years it compounded at +10.9% a year.
Context
- Financing cash flow amounted to 528.7% of revenue in FY2025, up 140.2 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +100.9% holds above the trailing-twelve-month pace of +33.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
CAD · from the cash flow
- Latest · FY2025
- 12.91M CAD
- Year-over-year change
- +45.4%
- 4-year CAGR
- +1.5%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.91M | +45.4% |
| FY2024 | 2024-12-31 | 8.88M | +63.1% |
| FY2023 | 2023-12-31 | 5.44M | -42.4% |
| FY2022 | 2022-12-31 | 9.46M | -22.3% |
| FY2021 | 2021-12-31 | 12.17M | — |
Financing Cash Flow vs competitors
How EDT.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +33.8% is the 5th highest of 8, against a peer median of +168.5%.
- Financing cash flow amounts to 418.6% of revenue for EDT.TO, versus a peer median of 69.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$399.12M CAD | +168.5% | — | 128.4% | |
| LTM Mar 2026 | $122.16M USD | +399.3% | +78.9% | — | |
| LTM Mar 2026 | $45.54M USD | -215.7% | +178.1% | 89.4% | |
PRN.TOProfound Medical Corp. | LTM Mar 2026 | $42.16M USD | +23.9% | +81.2% | 224.7% |
| LTM Mar 2026 | $25.62M USD | +311.3% | +6.4% | 50.1% | |
| LTM Mar 2026 | CA$11.56M CAD | +33.8% | +10.9% | 418.6% | |
| LTM Mar 2026 | CA$9.76M CAD | +1148.2% | — | 3.1% | |
| LTM Mar 2026 | CA$7.38M CAD | -123.3% | +148.2% | 11.1% | |
| Peer median (excluding EDT.TO) | — | +168.5% | +81.2% | 69.8% | |
Competitors are the stored peer set for EDT.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (8.79M) | (11.25M) | (15.66M) | (15.4M) | (47.69M) |
| Depreciation & Amortization | 294K | 272K | 218K | 251K | 250K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.26M | 1.2M | 1.49M | 1.68M | 2.12M |
| Change in Working Capital | (1.76M) | 579K | (406K) | 1.01M | (189K) |
| Accounts Receivables | 55K | (877K) | 870K | (265K) | 246K |
| Inventory | (51K) | (47K) | (26K) | 137K | (148K) |
| Accounts Payables | (1.11M) | 1.65M | (267K) | (51K) | (265K) |
| Other Working Capital | (656K) | (142K) | (983K) | 1.19M | (22K) |
| Other Non-Cash Items | 288K | (698K) | 3.64M | 3.64M | 33.88M |
| Operating Cash Flow | (8.7M) | (9.9M) | (10.72M) | (8.82M) | (9.52M) |
| Capital Expenditures | (483K) | (33K) | (185K) | (27K) | (195K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 158K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (325K) | (33K) | (185K) | (27K) | (195K) |
| Debt Repayment | (113K) | 3.71M | 3.93M | 9.74M | 9.67M |
| Common Stock Issued | 10M | 4.03M | 0 | 1.15M | 3.4M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.28M | 1.72M | 1.51M | (2.02M) | (155K) |
| Financing Cash Flow | 12.17M | 9.46M | 5.44M | 8.88M | 12.91M |
| Effect of Forex Changes | (56K) | 0 | 0 | 0 | 0 |
| Net Change in Cash | 3.08M | (476K) | (5.46M) | 36K | 1.08M |
| Free Cash Flow | (9.18M) | (9.93M) | (10.91M) | (8.85M) | (9.72M) |
Spectral Medical Inc.
TSX:EDT.TO
Intrinsic Alpha fair value
Locked
Current Price
$1.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.